Charles Dougherty Email

CEO . Vivasc Therapeutics

Current Roles

Employees:
2
Revenue:
$201k
About
Vivasc Therapeutics is an early stage, pre-clinical cardiac drug development company. We are utilizing the proprietary Cardiac Targeting Peptide (CTP) platform technology to deliver various cargo exclusively to cardiomyocytes in a non-invasive manner. We are actively seeking: Joint development partners for our lead compound, CTP-amio, for the treatment of arrhythmias (atrial fibrillation and ventricular tachycardia) Partners to use CTP as a platform vector to deliver other therapeutic cargo (oligonucleotides, peptides, proteins, drugs, nanoparticles, stem cell therapies, etc.) exclusively to cardiomyocytes
Vivasc Therapeutics Address
2403 Sidney St
Pittsburgh, PA
United States
Vivasc Therapeutics Email